Autopsy report · NCT00281996

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

“Closed to accrual to allow enrollment on another more promising trial.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Northwestern University

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

Gemcitabine; Imatinib mesylate

Participants

19

Sites

1

Countries

United States

Trials that died the same way

• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
  “Study closed to enrollment due to low accrual.” (77% match in meaning)
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
  “Enrollment held for toxicity evaluation; then closed due to competing trial” (77% match in meaning)
• PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds
  “Administratively closed prior enrollment of participants.” (76% match in meaning)
• Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
  “"the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"” (74% match in meaning)
• Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
  “The study was closed to enrollment due to slow accrual.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.